VivoSim logs first China commercial orders for NAMkind GI toxicology, efficacy testing services
Share
Listen to the news
VivoSim logs first China commercial orders for NAMkind GI toxicology, efficacy testing services
  • VivoSim reported first commercial sales in mainland China for its NAMkind toxicology screening and GI efficacy testing services.
  • Two paid engagements signed with a Shanghai-based oncology biotech, plus a Chengdu-based pharmaceutical company, via local distributor Tekon.
  • Orders cover GI toxicology screening, plus GI efficacy profiling for candidate molecules in oncology, plus other disease areas.
  • Company said the two orders represent a meaningful share of contracted revenue to date, marking an Asia-Pacific expansion milestone.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending